Strides Arcolab gets USFDA nod for Adenosine injection

Drug firm Strides Arcolab today said it has received approval from the US health regulator for additional package size of Adenosine injection used for treating cardiac problems.

The approval has been given by the United States Food and Drug administration (USFDA) for Adenosine injection USP in the strength of 3 mg/MI packaged in 12 mg/4 mL single dose vials, Strides Arcolab said filing to the Bombay Stock Exchange.

The product will be launched in the US market under a partnership between Strides and Sagent Pharmaceuticals. Strides is developing more than 25 injectable products for the US market which will be marketed by Sagent.

Adenosine is generic equivalent of Astellas Pharmaceuticals' Adenoscan.

According to September IMS data, the US innovator market for Adenosine presentations was nearly $94 million, Strides said.

The company has already received approvals for Adenosine injection in the strength of 60 mg per 20 ml and 90 mg per 30 ml vials, it added.

Shares of strides Arcolab were today trading at Rs 415.15 in the afternoon trade at BSE, up 1.62 per cent from its previous close.